Crinetics Pharmaceuticals Set to Update on Financial Progress
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), a leading player in the development of novel therapeutics for endocrine diseases, is ready to report its financial performance for the second quarter of 2025. This highly anticipated announcement is scheduled for the afternoon of August 7, 2025, following the market's close.
Details of the Upcoming Financial Results
During this upcoming financial results conference call, company executives will discuss various financial metrics and provide an overview of their business strategies. The call will begin at 4:30 p.m. Eastern Time, and all interested parties are encouraged to participate as management shares insights into Crinetics' journey in the pharmaceutical landscape.
How to Participate in the Conference Call
For those looking to join the call, Crinetics Pharmaceuticals provides two dial-in options:
- Domestic Participants: 1 833-470-1428
- International Participants: 1 404-975-4839
- Access Code: 899803
Join the Webcast for Live Updates
In addition to the dial-in numbers, stakeholders can access a live webcast of the conference call. To ensure full access, participants are advised to connect at least 15 minutes early. The link for the webcast will be accessible on the Crinetics Pharmaceuticals website in the Events section. This creates a great opportunity to stay informed directly from company leaders.
Company Overview and Innovative Therapeutics
Crinetics Pharmaceuticals specializes in the discovery and development of groundbreaking treatments for endocrine-related disorders, including tumors. One of their noteworthy investigational drugs is PALSONIFY (paltusotine), targeted at conditions such as acromegaly and carcinoid syndrome linked to neuroendocrine tumors. Meanwhile, Atumelnant is under development to treat congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
Continual Progress in Research and Development
The company remains focused on improving the lives of patients affected by various endocrine health issues. Their drug portfolio emphasizes the need for innovative therapies that address significant unmet medical needs. In-house drug discovery initiatives continue to foster the creation of oral, small-molecule entities aimed at treating conditions such as hyperparathyroidism, polycystic kidney disease, and even thyroid-related diseases like Graves' disease.
Investor Relations Information
All investors and analysts interested in receiving more detailed updates or specific inquiries regarding the financial results are encouraged to contact:
Gayathri Diwakar
Head of Investor Relations
Email: gdiwakar@crinetics.com
Phone: (858) 345-6340
Media Inquiries
For media-related questions or interviews, please contact:
Natalie Badillo
Head of Corporate Communications
Email: nbadillo@crinetics.com
Phone: (858) 345-6075
Frequently Asked Questions
What is the purpose of Crinetics' upcoming conference call?
The call is meant to present the company's financial results for Q2 2025 and discuss their future projects and strategies.
When will Crinetics' financial results be announced?
The results will be announced on August 7, 2025, after market closure.
How can I listen to the financial results call?
Participants can join via dial-in numbers or access the live webcast through Crinetics' website.
Who should I contact for investor inquiries?
Investor inquiries can be addressed to Gayathri Diwakar at Crinetics Pharmaceuticals.
What innovative drugs is Crinetics developing?
Crinetics is developing multiple drugs, including PALSONIFY for acromegaly and Atumelnant for adrenal conditions.
